Background-Women receive less evidence-based medical care than men and have higher rates of death after acute myocardial infarction (AMI). It is unclear whether efforts undertaken to improve AMI care have mitigated these sex disparities in the current era. 
D
espite advances in cardiovascular therapeutics and research and the associated decline in cardiovascular death, cardiovascular disease remains the leading cause of death in the United States. 1 Death from acute myocardial infarction (AMI) in the United States remains particularly elevated among women. In 2004, AMI claimed the lives of nearly 74 000 women in the United States. 1 Multiple reports have also shown increased early death among women presenting with AMI compared with their male counterparts. 2, 3 In addition, women receive less medical and invasive treatments after AMI compared with men. 4 -8 
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However, many of the aforementioned reports are currently outdated, and each examined only limited aspects of medical care and outcome among men and women presenting with AMI. Whether the sex disparities in care processes and death after AMI are still present in the current era and the extent to which differences in baseline risk account for any existing mortality rate gap remain a matter of constant debate and have important clinical implications.
Therefore, we conducted a comprehensive analysis of the association of sex with medical care and early death after AMI using a large contemporary national database. More specifically, we systematically compared the use of early medical treatments, reperfusion strategies, and invasive procedures, as well as the timeliness of mechanical and pharmacological reperfusion, and in-hospital death between men and women hospitalized with AMI. We also separately examined sex disparities in in-hospital mortality rates in the STelevation myocardial infarction (STEMI) subgroup.
Methods

Data Source and Study Sample
The primary data source was Get With the Guidelines-Coronary Artery Disease (GWTG-CAD), a registry and performanceimprovement initiative undertaken by the American Heart Association to enhance guidelines adherence among patients hospitalized with CAD. The overall GWTG program objectives were described previously. 9 -11 The database includes teaching and nonteaching, rural and urban, large and small hospitals from all census regions of the United States. Hospitals were required to submit data from consecutive patients. Data were collected by participating hospitals without financial compensation and entered by highly trained personnel. Admission staff, medical staff, or both recorded race/ ethnicity, usually as patients were registered. Case finding was predominantly based on clinical identification of patients with these diagnoses in most hospitals, frequently with additional confirmation by retrospective International Classification of Diseases, Ninth Revision coding. Data quality reports were generated regularly to summarize quality problems and provide feedback to the individual sites.
At the time of the analysis, the GWTG-CAD database included 84 900 patients admitted directly to non-national health service hospitals with AMI. Of those, we excluded patients on renal dialysis (nϭ1853; or 2.2% of the overall population), patients enrolling in clinical trials (nϭ115; 0.1%), patients with missing or invalid arrival dates or times (nϭ3682; 4.3%), patients with prolonged length of stay Ͼ30 days (nϭ789; 0.9%), and those with missing sex variable data (nϭ207; 0.2%). Exclusions were based on the fact that these small subgroups were usually not representative of real-world AMI patients and that meaningful analyses were not feasible in the absence of the aforementioned variable data.
The final study population included 78 254 patients hospitalized with AMI in 420 hospitals throughout the United States between January 2001 and April 2006. Patients discharged to other medical facilities were excluded from the analyses of in-hospital death and invasive procedures (nϭ7804 patients). Measures of the timeliness of reperfusion were available and reported in 10 480 patients with STEMI. Reperfusion measures were applicable to and analyzed only in the STEMI cohort (nϭ25 353). In-hospital death rates were equally available in 99.5% of all AMI and STEMI patients (70 105 and 23 015 patients, respectively).
Data Collection and Measures
Sex (female versus male) was the primary independent variable. The primary study outcome was in-hospital death. Secondary outcomes included clinical performance measures (early medical therapies, acute reperfusion therapies, timeliness of reperfusion parameters) and invasive procedures.
Guidelines-recommended early medical therapies included the following: aspirin use within 24 hours of arrival in AMI patients with no contraindication to the medication (nϭ70 360) and ␤-blocker use within 24 hours of arrival in AMI patients with no contraindication to the medication (nϭ64 681). Patients who died, left against medical advice, or were discharged within 24 hours of arrival were excluded from these analyses. Acute reperfusion therapies were analyzed in the reperfusion-eligible STEMI subpopulation and included the following: primary percutaneous coronary intervention (PCI), fibrinolytic therapy, and any reperfusion. Timeliness of reperfusion parameters included the proportion of STEMI patients who received fibrinolytic therapy within the American College of Cardiology/American Heart Association guidelines-recommended 30-minute door-to-needle (DTN) time and the proportion of STEMI patients who received primary PCI within the American College of Cardiology/American Heart Association guidelines-recommended 90-minute door-to-balloon (DTB) time. DTN was defined as the time from hospital arrival to initiation of fibrinolytic therapy, and DTB time was defined as the time from hospital arrival to first balloon inflation. Invasive procedures included cardiac catheterization, PCI, coronary artery bypass graft surgery (CABG), and overall revascularization. The STEMI subpopulation included 25 353 patients defined by the presence of initial ECG findings showing diagnostic ST-segment elevation or left bundle-branch block.
Statistical Analysis
For the descriptive analyses, patients' sociodemographic and medical history variables, baseline clinical characteristics, clinical performance measures, invasive procedures, and in-hospital mortality rates were compared between women and men. Percentages and meanϮSD values were reported to describe the distribution of categorical and continuous variables, respectively. Medians and interquartile ranges (25th to 75th) were reported for DTB and DTN times. Categorical and continuous variables were compared with the use of the 2 and Wilcoxon rank sum tests, respectively. Multivariable logistic regression analyses, with the use of the generalized estimating equations method 12 to adjust for clustering within hospitals, were performed to determine whether sex was independently associated with each measure and outcome. The regression model adjusted for the following covariates: age, race, body mass index (BMI), insurance type, systolic blood pressure, cardiac diagnosis, initial ECG with diagnostic ST-segment elevation or left bundlebranch block, diabetes, hypertension, hyperlipidemia, heart failure, previous myocardial infarction (MI), peripheral vascular disease, renal insufficiency, stroke, chronic obstructive pulmonary disease, and adult history of smoking. Odds ratios (ORs) with their 95% CIs were reported for women versus men for each measure and outcome. A probability value of Ͻ0.05 was considered statistically significant for all tests. All analyses were performed by the Duke Clinical Research Institute (Durham, NC) with the use of the Statistical Analysis System (SAS) software version 8.2 (SAS Institute, Cary, NC).
The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
Results
Patient Characteristics
The study population included 78 254 patients with AMI, of whom 39% (nϭ30 698) were women. In the overall AMI cohort, women were older, less likely to be white, and more likely to have Medicare or Medicaid insurance and had lower BMI (Table 1) . Women presenting with AMI had more comorbidities, except for hyperlipidemia, smoking history, and a prior MI history, which were more common among men. Women were also less likely to present with STEMI (28.2% versus 35.1%; PϽ0.0001) and had higher systolic blood pressure and ejection fraction on admission.
Clinical Performance Measures
Women presenting with AMI were less likely than their male counterparts to receive aspirin and ␤-blockers within 24 hours of arrival (91.0% versus 93.3% and 84.7% versus 87.2%; each with PϽ0.0001) ( Table 2 ). Overall, 67% of patients in the STEMI subpopulation received acute reperfusion therapy (primary PCI or fibrinolytic therapy), with lower rates observed among STEMI women (56.3% versus 73.0%;
PϽ0.0001).
Compared with men, women with STEMI were less likely to receive fibrinolytic therapy alone, primary PCI, or the combination of fibrinolytic therapy and PCI (5.1% versus 6.2%, 47.3% versus 61.1%, and 3.9% versus 5.8%, respectively; PϽ0.0001). Women presenting with STEMI were also less likely to achieve timely DTN (28.3% versus 35.2%; Pϭ0.0005) and timely DTB (39.0% versus 44.8%; PϽ0.0001). Median DTN and DTB times for women versus men were 47 versus 39 minutes and 103 versus 95 minutes, respectively, each with PϽ0.0001 ( Table 2) .
The sex disparities in the aforementioned clinical performance measures persisted after multivariable adjustment and remained highly statistically significantly different (Table 3) .
Invasive Procedures
Compared with men, women with AMI were less likely to undergo a cardiac catheterization procedure during their index hospitalization (45.6% versus 56.2%; PϽ0.0001), PCI (36.1% versus 52.3%; PϽ0.0001), CABG (5.4% versus 9.2%; PϽ0.0001), and any revascularization (40.9% versus 60.2%; PϽ0.0001) ( Table 2 ). These sex differences in invasive procedures persisted after multivariable adjustment (Table 3) .
In-Hospital Mortality Rates
Women had higher unadjusted in-hospital mortality rates in the overall AMI cohort ( 
1).
To examine the attributable effects of treatments and clinical performance measures in closing the residual sex gap in death rates among STEMI patients, we further excluded STEMI patients who died (nϭ475) or left against medical advice (nϭ34) in the initial 24 hours of hospitalization from the analyses (52% were women), reasoning that these patients did not have time to receive therapies. After these patients were excluded, the adjusted in-hospital mortality rate was no longer different between women and men presenting with STEMI (1.02; 95% CI, 0.91 to 1.15; Pϭ0. 7) , indicating that the residual sex differences in adjusted in-hospital mortality rates were accounted for by excess very early deaths (in the initial 24 hours) among women with STEMI.
During the initial 24 hours of hospitalization, women with STEMI were more than twice as likely to die or leave against medical advice compared with men (3.4% versus 1.6%; PϽ0.0001). Among those STEMI patients who died or left against medical advice in the initial 24 hours, women were older than men (78.4Ϯ13.8 versus 68.2Ϯ15.5 years; PϽ0.0001) and more frequently had hypertension and heart failure but had lower BMI and less often smoked (data not shown 
Discussion
The present study demonstrates that women presenting with AMI had adjusted in-hospital death rates similar to those of men but were less likely to receive early medical treatments, acute reperfusion therapies, timely pharmacological and mechanical reperfusion, and invasive procedures. Women presenting with AMI were older and had overall higher baseline risk profile than men, which explained their higher unadjusted in-hospital mortality rates. On the other hand, women presenting with STEMI had higher adjusted in-hospital mortality rates than men. The residual sex-based disparity in adjusted in-hospital mortality rates after STEMI was accounted for by an excess of very early deaths (in the initial 24 hours of hospitalization) among STEMI women, who appeared to receive less invasive procedures and revascularization during this time period. After multivariable adjustment, persistent sex disparities after AMI were observed in all clinical performance measures and invasive procedures.
Similar to prior reports, our contemporary analysis confirms the higher unadjusted early death of women hospitalized with AMI compared with men 2,3,13,14 and demonstrates that the mortality rate gap is even larger in the higher-risk STEMI subpopulation. As reported previously, women are older, have more comorbidities than men when presenting with AMI, 3, 7 and are less likely to present with STEMI. 3 Multiple studies have shown the increased death among women to be related to their higher baseline risk. 2 16 Women hospitalized for AMI have also been shown to receive less aggressive medical and invasive treatments. 4 -8 Although some have found that the treatment differences are small and do not affect early death, 17 others have attributed the sex gap in death after AMI to these treatment inequalities. 5, 8 Thus, the extent to which mortality rate differences between men and women are related to discrepancies in baseline risk versus treatment bias remains a matter of constant debate. The controversy in the literature stems largely from differences in the studied populations and from methodological variations, including differences in definitions and adjustment analyses.
In the present study, the mortality rate gap was no longer observed after a comprehensive multivariable adjustment, which lends support to the notion that sex by itself, in the current era, does not independently predict early death after AMI among hospitalized patients. The mortality rate gap, however, persisted among STEMI patients and was possibly accounted for by a higher rate of very early deaths (in the initial 24 hours of hospitalization) among women. In 1 report paralleling our findings, the largest sex disparity in death rates after AMI occurred in the early hospitalization period, namely, during the initial 5 days of hospitalization. 14 Another study demonstrated increased case fatality after AMI in the initial 24 hours of hospitalization but did not find sex differences in case fatality during this time period. 18 Both of these reports included overall AMI patients and did not examine STEMI patients in particular. 14, 18 In our analysis, women who sustained very early deaths in our STEMI subpopulation were older, had slightly different risk profiles, and underwent revascularization and reperfusion less frequently than men. Whether the excess very early death among *ORs, which are for women vs men, were adjusted for age, race, BMI, insurance type, systolic blood pressure, cardiac diagnosis, initial ECG with diagnostic ST-segment elevation or left bundle-branch block, diabetes, hypertension, hyperlipidemia, heart failure, previous MI, peripheral vascular disease, renal insufficiency, stroke, chronic obstructive pulmonary disease, and adult history of smoking. The generalized estimation equations approach was also employed to adjust for clustering within hospitals.
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Figure.
In-hospital mortality rates among hospitalized women and men in the overall AMI cohort and in the STEMI subpopulation.
STEMI women was related to treatment differences or to sicker patients dying before receiving adequate therapies was difficult to discern. It is likely, though, that both were important contributing factors. Regardless, women presenting with STEMI appear to be at high risk of dying in the initial 24 hours and to represent a subgroup of patients in whom prompt and aggressive therapies are warranted. It is important to note that these post hoc findings are exploratory in nature and need confirmation in larger analyses. Of note, our data included hospitalized AMI patients only and did not account for out-of-hospital deaths. Evidence suggests that AMI women are more likely to survive and reach the hospital compared with their male counterparts. 15, 19 One report even contends that the higher probability among women of surviving to reach the hospital counterbalances their subsequent excess death. 15 Therefore, it is conceivable that such a selection bias might have enriched hospitals with higher-risk AMI women and explained our observed sex differences in risk profiles and mortality rates.
In addition to providing a contemporary glimpse at sex disparities in early death after AMI, a distinct advantage of our study is that it confirms the existence of concomitant disparities in clinical performance measures using a systematic review of multiple care processes. Complementing a wealth of prior studies, 4 -8 we have described consistently lower use of early medical treatments and timely reperfusion among hospitalized women presenting with AMI. This highlights the persisting opportunities to improve healthcare among these patients. This is especially important given that the described treatment biases can be more readily rectified in the controlled hospital setting, in contradistinction to the more challenging task of altering primary and secondary prevention therapies in the out-of-hospital setting. Besides differences in baseline risk, other modifiable factors and contributing etiologies may further explain the observed discrepancies in treatments and outcome after AMI between women and men. These factors are worth examining in future analyses and may include, but are not limited to, race, adherence to guidelines-recommended treatments, delayed hospital presentation, and delayed AMI diagnosis among women.
We were unable to fully ascertain appropriateness of revascularization in our analysis given the lack of angiographic data. Younger women, for example, are known to have higher incidence of coronary in situ thrombosis, smaller vessels, and more vasospastic disease. 20 Therefore, one may argue that the lower PCI use among women may reflect appropriate physicians' decisions. The lower use of CABG can also be ascribed to differences in surgical suitability, and physicians' reticence to administer fibrinolytics to women may be attributed to their higher proclivity to suffer intracranial hemorrhage and other complications. 21, 22 On the other hand, many of the treatments and measures examined in our analysis are proven therapies 13, 23 and accepted clinical performance measures 24 for both women and men after AMI. Disparities in the use of early aspirin and ␤-blocker therapies, which were recorded only in patients with no contraindication to these medications, and the disparities in DTB and DTN times are hard to attribute to anything but inappropriate treatment biases. Evidence also suggests that patients' preferences in dictating treatments, which were not captured in our data, usually account only for a very small fraction of the sex differences in care processes. 25 Overall, the persistence and magnitude of sex disparities after multivariable adjustment and their existence across several clinical performance measures indicate the presence of inappropriate sex-based treatment biases after AMI in the contemporary era. It is also noteworthy to emphasize that overall rates of use of most treatments and measures were less than ideal among both women and men, suggesting that there is room for improving overall care for all AMI patients.
Overall, our analysis has several strengths, including the following: its inclusion of a community-based contemporary patient population, inclusive of all regions of the United States; its comprehensive evaluation of multiple processes of care and clinical data; and the robustness and consistency of our findings. The GWTG database utilized carefully defined data entries, standardized diagnostic criteria, and regular quality assessment. The GWTG database included patients with confirmed AMI diagnosis at discharge. This is an important distinction from other registries that enroll patients with suspected AMI at presentation, many of whom are determined to be misdiagnosed. Consent procedures and eligibility for specific treatments were not required for enrollment in the GWTG program, which minimizes bias and increases our study generalizability. On the other hand, our study has several limitations. The GWTG hospitals are self-selected and may not be fully representative of national care patterns and clinical outcomes. We had no data on predischarge and postdischarge mortality and morbidity. Moreover, eligibility for treatment was based on documentation in the medical record and was thus dependent on the accuracy of this documentation. Finally, there might be other measured or unmeasured confounding variables that, had they been adjusted for, would have modified the relationship between sex and in-hospital mortality rates.
In conclusion, women presenting with AMI had higher unadjusted in-hospital mortality rates than men. After adjustment for baseline risk and clinical characteristics, sex-based differences in early death after AMI were no longer observed overall but remained apparent in the STEMI subpopulation and were possibly accounted for primarily by excess death among women in the initial 24 hours of hospitalization. Evidence of lower use of guidelines-based treatments and delayed reperfusion among women compared with men highlights the existing opportunities to improve the provision of healthcare among women hospitalized with AMI. Special attention should be given to those at highest risk, especially women with STEMI during their early hospitalization period.
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